SELLAS Life Sciences Announces First Quarter 2025 Financial Results
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS), a company dedicated to developing innovative cancer therapies, has released its financial results for the first quarter of 2025. As of March 31, 2025, SELLAS reported a cash and cash equivalents balance of approximately $28.4 million. This solid financial standing positions the company for upcoming clinical milestones that promise to bolster its future endeavors.
Positive Outcomes in Ongoing Trials
According to Angelos Stergiou, MD, ScD h.c., President and CEO of SELLAS, the company is showing promising momentum across its research and development pipeline. The ongoing Phase 2 trial of SLS009, focused on relapsed/refractory Acute Myeloid Leukemia (AML), has yielded significant results. Specifically, patients with AML-Myelodysplasia-Related Changes (AML-MRC) have achieved a median overall survival (mOS) of 8.9 months, and all patients resistant to venetoclax-based regimens have shown an mOS of 8.8 months, drastically exceeding the historical benchmark of 2.5 months.
Impressive Overall Response Rates (ORR)
The efficacy of SLS009 is further underscored by the trial reporting a 67% overall response rate in AML-MRC patients and a 46% response rate in all evaluable patients, outpacing a targeted ORR of 20%. With data continuously monitored, full trial results and feedback from the FDA are expected in the first half of 2025.
Future Presentations and Analysis
SELLAS anticipates presenting additional data on SLS009, especially its efficacy in ASXL1-mutated colorectal cancer lines, during the ASCO event. The full topline data from the Phase 2 trial is awaited, alongside the final analysis of the pivotal Phase 3 REGAL trial for Galinpepimut-S (GPS) in AML, demonstrating the company's active engagement in advancing oncology therapeutics.
Pediatric Acute Lymphoblastic Leukemia (ALL) Advances
A noteworthy highlight includes findings from the NIH-funded PIVOT program, which illustrates SLS009's effectiveness in pediatric ALL patient-derived xenografts. The studies have shown that average survival rates in treated mice were approximately tripled compared to controls, signifying a significant leap in therapeutic potential against childhood cancers.
Financial Overview
In terms of expenses, research and development costs for Q1 2025 totaled $3.2 million, a decrease from $5.1 million the previous year. This reduction stems from lower clinical trial expenses and drug supply costs, highlighting effective financial management as the company navigates through various developmental stages of its therapies.
General and Administrative Costs
The company also reported a decline in general and administrative expenses, which amounted to $2.9 million for the quarter, down from $4.5 million in the same period last year. This decline reflects a streamlined operational approach following notable changes in personnel and a focus on efficient resource utilization.
Investor Relations and Contact Information
As SELLAS continues to thrive and push the boundaries of cancer treatment, investor inquiries can be directed to Bruce Mackle, Managing Director at LifeSci Advisors, LLC. Interested parties can reach out via email at SELLAS@lifesciadvisors.com for more information regarding the company’s ongoing projects and investment opportunities.
Frequently Asked Questions
What is SELLAS Life Sciences primarily focused on?
SELLAS Life Sciences is focused on developing novel therapies for a wide range of cancer indications, particularly through its lead candidate SLS009.
What recent trial results have been announced by SELLAS?
The latest results from the Phase 2 trial of SLS009 in relapsed/refractory AML showed a median overall survival of 8.9 months for AML-MRC patients.
Who is the current CEO of SELLAS Life Sciences Group?
Angelos Stergiou, MD, ScD h.c. serves as the President and CEO of SELLAS Life Sciences Group.
What are the expected upcoming milestones for SELLAS?
SELLAS anticipates the presentation of additional data on SLS009 during ASCO and the final analysis of the Phase 3 REGAL trial later this year.
How can investors contact SELLAS for more information?
Investors can reach Bruce Mackle at LifeSci Advisors via email at SELLAS@lifesciadvisors.com.
